Sanofi Names Industry Veteran to Lead Global Specialty Care Division

Sanofi has announced the appointment of Manuela Buxo as the head of its global specialty care business unit. The French pharmaceutical giant is shifting focus towards more specialized and innovative treatments for chronic diseases, with Buxo’s appointment aimed at propelling this strategy forward. Buxo brings a wealth of experience in the biopharmaceutical industry, having spent over 15 years working at various top-tier companies including Pfizer and Teva Pharmaceuticals. Her expertise spans product development, commercialization, and regulatory affairs, making her an ideal candidate to lead Sanofi’s specialty care division. Under Buxo’s leadership, Sanofi aims to expand its portfolio of treatments for conditions such as diabetes, kidney disease, and multiple sclerosis. The company is also investing heavily in research and development, with a focus on creating novel therapies that address the unmet needs of patients worldwide. The appointment marks a significant shift in Sanofi’s strategy, as the company seeks to differentiate itself from its competitors by focusing on more complex and innovative treatments. Buxo’s appointment is seen as a key move in this regard, as she brings with her a deep understanding of the industry and a proven track record of driving business growth. Sanofi’s specialty care division has been experiencing significant challenges in recent years, including increased competition from generic medications and rising healthcare costs. However, under Buxo’s leadership, the company is confident that it can turn around its fortunes and deliver strong growth and returns for shareholders.